Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Kirk Look to speak today

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Sep 11, 2024 2:42pm

257 Views

Post# 36219005

RE:RE:RE:RE:RE:Kirk Look to speak today

do you mean, like the comment that they have had the data since MAY...

and it's taken them 4 months to assess this. Good Lord they only had 48 patients to begin with... and that's divided into thirds per cohort...

market seems excited though, only down 2 1/2 %

<< Previous

Bullboard Posts

Next >>

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!